^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jelmyto (mitomycin urothelial gel)

    i
    Other names: UGN-101
    Company:
    UroGen
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    21d
    SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Rutgers, The State University of New Jersey | Initiation date: Aug 2025 --> Jun 2026
    Trial initiation date
    |
    gemcitabine • Jelmyto (mitomycin urothelial gel)
    24d
    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov)
    P1, N=49, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2026 --> Jan 2028 | Trial primary completion date: Aug 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    cisplatin • paclitaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • oxaliplatin • irinotecan • daunorubicin • leucovorin calcium • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    4ms
    SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Rutgers, The State University of New Jersey | Initiation date: Apr 2025 --> Aug 2025
    Trial initiation date
    |
    gemcitabine • Jelmyto (mitomycin urothelial gel)
    7ms
    In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • docetaxel • Jelmyto (mitomycin urothelial gel) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    8ms
    Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (clinicaltrials.gov)
    P2, N=252, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    9ms
    uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, UroGen Pharma Ltd. | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial primary completion date • Real-world evidence
    |
    Jelmyto (mitomycin urothelial gel)
    10ms
    SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Rutgers, The State University of New Jersey
    New P2 trial
    |
    gemcitabine • Jelmyto (mitomycin urothelial gel)
    11ms
    A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer (clinicaltrials.gov)
    P3, N=50, Not yet recruiting, UroGen Pharma Ltd.
    New P3 trial
    |
    Jelmyto (mitomycin urothelial gel)
    1year
    Transarterial Chemoembolization for the Treatment of Lung Cancer and Lung Metastases (clinicaltrials.gov)
    P2, N=30, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Jelmyto (mitomycin urothelial gel)
    1year
    In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    gemcitabine • docetaxel • Jelmyto (mitomycin urothelial gel) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    over1year
    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov)
    P1, N=49, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • doxorubicin hydrochloride • oxaliplatin • irinotecan • daunorubicin • leucovorin calcium • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    over1year
    SHIELD-RT: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=475, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical